Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Esperion TherapeuticsESPR -0.31%41 3-Year Dividend Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates ESPR with a GF Score™ of 41/100 and a GF Value™ of $2.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 349 Drug Manufacturers companies, Esperion Therapeutics ranks worse than 286532.66% on this metric.
The historical rank and industry rank for Esperion Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:
ESPR's 3-Year Dividend Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.7 * Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics 3-Year Dividend Growth Rate Related Terms>
ESPR vs AMPH, NIKA, BIOA: 3-Year Dividend Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics 3-Year Dividend Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's 3-Year Dividend Growth Rate falls into.
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 0.00% mean?
Esperion Therapeutics (ESPR) has a 3-Year Dividend Growth Rate of 0.00% as of Mar. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Esperion Therapeutics and its competitors. According to the industry distribution chart, Esperion Therapeutics ranks #999999 out of 349 companies in the Drug Manufacturers industry.
Is Esperion Therapeutics' 3-Year Dividend Growth Rate too high?
Esperion Therapeutics' current 3-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, Esperion Therapeutics ranks #999999 out of 349 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Esperion Therapeutics has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' 3-Year Dividend Growth Rate compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #999999 out of 349 companies for 3-Year Dividend Growth Rate. This places Esperion Therapeutics in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 7.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Drug Manufacturers company?
The median 3-Year Dividend Growth Rate among Drug Manufacturers companies is 7.70, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Esperion Therapeutics and its competitors. For the Drug Manufacturers industry, the median 3-Year Dividend Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Esperion Therapeutics's current 3-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.27, compared to a current price of $3.18 — trading 40.1% above its estimated fair value. The current 3-Year Dividend Growth Rate is 0.00%. Esperion Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current 3-Year Dividend Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Esperion Therapeutics (ESPR) Overvalued in 2026?
Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued.
The current stock price of $3.18 is trading 40.1% above its estimated GF Value™ of $2.27.
GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.
Key valuation signals for ESPR:
3-Year Dividend Growth Rate: 0.00%
GF Value™: $2.27 vs. price of $3.18 (40.1% above fair value)
No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
41GF Score
Get the complete analysis for ESPR
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESPR has been successfully added to your 
